PBMCs protein expression profile in relapsing IFN-treated multiple sclerosis: A pilot study on relation to clinical findings and brain atrophy

J Neuroimmunol. 2009 May 29;210(1-2):80-6. doi: 10.1016/j.jneuroim.2009.03.002. Epub 2009 Mar 29.

Abstract

This cross-sectional study investigated with two-dimensional gel electrophoresis coupled to MALDI-TOF and MRI the relationship between PBMCs protein expression profile and whole-brain atrophy in 16 unselected RR-MS IFN-treated patients compared with 6 RR IFN-untreated and 12 matched healthy control subjects. Grey/white matter fraction, T1/T2 lesion load and clinical variables were considered too. Twenty six proteins showed significant differential expression among RR IFN-treated patients and control samples. Four of these (IN35, GANAB, PP1B, SEPT2) resulted correlated with clinical and MRI findings in RR IFN-treated MS patients. Future clinical applications remain to be validated by other techniques and confirmed by a larger study.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Atrophy / pathology*
  • Atrophy / physiopathology
  • Brain / pathology*
  • Brain / physiopathology
  • Cross-Sectional Studies
  • Disease Progression
  • Electrophoresis, Gel, Two-Dimensional
  • Female
  • Humans
  • Leukocytes, Mononuclear / immunology
  • Leukocytes, Mononuclear / metabolism*
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / immunology
  • Multiple Sclerosis, Relapsing-Remitting / metabolism*
  • Multiple Sclerosis, Relapsing-Remitting / pathology*
  • Nerve Fibers, Myelinated / pathology
  • Phosphoric Monoester Hydrolases / analysis
  • Phosphoric Monoester Hydrolases / metabolism
  • Pilot Projects
  • Predictive Value of Tests
  • Proteomics / methods
  • Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
  • Young Adult

Substances

  • Phosphoric Monoester Hydrolases